- What Makes Galderma Group AG - Unsponsored ADR (GALDY) a New Strong Buy Stock
May 5, 2026
Galderma Group AG - Unsponsored ADR (GALDY) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.
The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.
The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are mostly driven by subjective factors that are hard to see and measure in real time.
Therefore, the Zacks rating upgrade for Galderma Group AG - Unsponsored ADR basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.
Most Powerful Force Impacting Stock Prices
The change in a company's future earnings potential, as reflected in earnings estimate revisions, has proven to be strongly correlated with the near-term price movement of its stock. That's partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their bulk investment action then leads to price movement for the stock.
Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for Galderma Group AG - Unsponsored ADR imply an improvement in the company's underlying business. Investors should show their appreciation for this improving business trend by pushing the stock higher.
Harnessing the Power of Earnings Estimate Revisions
As empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, tracking such revisions for making an investment decision could be truly rewarding. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>> .
Story Continues
Earnings Estimate Revisions for Galderma Group AG - Unsponsored ADR
For the fiscal year ending December 2026, this company is expected to earn $0.98 per share, which is unchanged compared with the year-ago reported number.
Analysts have been steadily raising their estimates for Galderma Group AG - Unsponsored ADR. Over the past three months, the Zacks Consensus Estimate for the company has increased 14%.
Bottom Line
Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of "buy" and "sell" ratings for its entire universe of more than 4,000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a "Strong Buy" rating and the next 15% get a "Buy" rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.
You can learn more about the Zacks Rank here >>>
The upgrade of Galderma Group AG - Unsponsored ADR to a Zacks Rank #1 positions it in the top 5% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Galderma Group AG - Unsponsored ADR (GALDY) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
- What Makes Galderma Group AG - Unsponsored ADR (GALDY) a New Strong Buy Stock
May 5, 2026 · zacks.com
Galderma Group AG - Unsponsored ADR (GALDY) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Galderma Group AG (GALDY) Q1 2026 Sales/Trading Call Transcript
Apr 23, 2026 · seekingalpha.com
Galderma Group AG (GALDY) Q1 2026 Sales/Trading Call Transcript
- Galderma Shareholders Approve All Annual General Meeting Proposals
Apr 22, 2026 · businesswire.com
ZUG, Switzerland--(BUSINESS WIRE)--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, announced that shareholders approved all proposals put forward by the Board of Directors at its Annual General Meeting (AGM), held earlier today via live webcast. This includes the payment of a gross dividend of 0.35 CHF per dividend-bearing share1, to be distributed out of reserves from capital contributions. Shareholders approved the election of Harry Kirsch as independent member of the.
- GALDERMA SHAREHOLDERS APPROVE ALL ANNUAL GENERAL MEETING PROPOSALS
Apr 22, 2026
ZUG, SWITZERLAND--(BUSINESS WIRE)--GALDERMA GROUP AG (SIX:GALD), THE PURE-PLAY DERMATOLOGY CATEGORY LEADER, ANNOUNCED THAT SHAREHOLDERS APPROVED ALL PROPOSALS PUT FORWARD BY THE BOARD OF DIRECTORS AT ITS ANNUAL GENERAL MEETING (AGM), HELD EARLIER TODAY VIA LIVE WEBCAST. THIS INCLUDES THE PAYMENT OF A GROSS DIVIDEND OF 0.35 CHF PER DIVIDEND-BEARING SHARE1, TO BE DISTRIBUTED OUT OF RESERVES FROM CAPITAL CONTRIBUTIONS. SHAREHOLDERS APPROVED THE ELECTION OF HARRY KIRSCH AS INDEPENDENT MEMBER OF THE.
- Baird International And Global Growth Funds Q1 2026 Portfolio Activity
Apr 14, 2026 · seekingalpha.com
ASML reported solid 4Q25 results and record bookings due to strong AI demand for DRAM and advanced logic, and FY2026 guidance is above consensus. Adyen reported December quarter results slightly below consensus expectations, with net revenue growing 19% y/y. For the Baird Chautauqua International Growth Fund, 60% of companies that reported earnings during the quarter were in line with or exceeded consensus estimates.
- Galderma Group AG (GALDY) Q4 2025 Earnings Call Transcript
Mar 5, 2026 · seekingalpha.com
Galderma Group AG (GALDY) Q4 2025 Earnings Call Transcript
- European Stocks That May Be Trading Below Their Estimated Value In February 2026
Feb 17, 2026
As European markets experience volatility amid concerns about AI disruption and digest strong U.S. job data, the pan-European STOXX Europe 600 Index has reached new highs but remains largely unchanged. In this environment, identifying stocks that may be trading below their estimated value can offer potential opportunities for investors looking to capitalize on market inefficiencies.
Top 10 Undervalued Stocks Based On Cash Flows In Europe
Name Current Price Fair Value (Est) Discount (Est) Neste Oyj (HLSE:NESTE) €20.54 €41.08 50% Nemetschek (XTRA:NEM) €64.20 €128.11 49.9% Metriks AI. Società Benefit (BIT:MTK) €3.38 €6.64 49.1% KB Components (OM:KBC) SEK39.25 SEK77.43 49.3% Grieg Seafood (OB:GSF) NOK72.70 NOK143.53 49.3% Galderma Group (SWX:GALD) CHF150.80 CHF299.99 49.7% Eltel (OM:ELTEL) SEK9.26 SEK18.35 49.5% Elkem (OB:ELK) NOK26.86 NOK53.16 49.5% cBrain (CPSE:CBRAIN) DKK70.70 DKK141.04 49.9% B&S Group (ENXTAM:BSGR) €5.85 €11.66 49.8%
Click here to see the full list of 196 stocks from our Undervalued European Stocks Based On Cash Flows screener.
We're going to check out a few of the best picks from our screener tool.
Pharma Mar
Overview: Pharma Mar, S.A. is a biopharmaceutical company specializing in the research, development, production, and commercialization of bio-active principles for oncology across various global markets including Spain, China, Germany, Ireland, France, the rest of the European Union and the United States; it has a market cap of approximately €1.32 billion.
Operations: The company's revenue from oncology amounts to €179.94 million.
Estimated Discount To Fair Value: 34.4%
Pharma Mar is trading at €76.45, significantly below its estimated future cash flow value of €116.52, indicating it may be undervalued based on cash flows. Analysts forecast earnings to grow 36.1% annually, outpacing the Spanish market's 7.3%. Despite slower revenue growth of 17.9%, it exceeds the market average of 5.5%. The company's recent presentation at the J.P. Morgan Healthcare Conference highlights ongoing strategic initiatives and potential investor interest.
The growth report we've compiled suggests that Pharma Mar's future prospects could be on the up. Click here to discover the nuances of Pharma Mar with our detailed financial health report.BME:PHM Discounted Cash Flow as at Feb 2026
Koskisen Oyj
Overview: Koskisen Oyj is a company in the wood industry with operations in Finland, Japan, Germany, Poland, other European countries, and internationally; it has a market cap of €212.03 million.
Operations: Koskisen Oyj generates revenue from its operations in the wood industry across Finland, Japan, Germany, Poland, other European countries, and internationally.
Story Continues
Estimated Discount To Fair Value: 29.9%
Koskisen Oyj is trading at €8.8, considerably below its estimated future cash flow value of €12.56, reflecting potential undervaluation based on cash flows. The company forecasts earnings growth of 24.2% annually, surpassing the Finnish market's 13.3%, while revenue is expected to grow by 6.7% per year, outpacing the market's 4.2%. Recent earnings show a rise in annual sales to €354.94 million and a slight increase in net income to €8.62 million for 2025.
According our earnings growth report, there's an indication that Koskisen Oyj might be ready to expand. Click to explore a detailed breakdown of our findings in Koskisen Oyj's balance sheet health report.HLSE:KOSKI Discounted Cash Flow as at Feb 2026
Vitrolife
Overview: Vitrolife AB (publ) supplies assisted reproduction products across Europe, the Middle East, Africa, Asia-Pacific, and the Americas with a market cap of SEK12.11 billion.
Operations: The company's revenue segments consist of Genetics at SEK1.39 billion, Consumables at SEK1.37 billion, and Technologies at SEK684 million.
Estimated Discount To Fair Value: 38.4%
Vitrolife is trading at SEK 89.4, significantly below its estimated future cash flow value of SEK 145.22, highlighting a potential undervaluation based on cash flows. Despite recent challenges including a goodwill impairment of SEK 5.4 billion and restructuring costs of SEK 55 million, the company is expected to return to profitability within three years with forecasted earnings growth exceeding market averages. Revenue growth is anticipated at 6.4% annually, outpacing the Swedish market's decline.
In light of our recent growth report, it seems possible that Vitrolife's financial performance will exceed current levels. Get an in-depth perspective on Vitrolife's balance sheet by reading our health report here.OM:VITR Discounted Cash Flow as at Feb 2026
Next Steps
Dive into all 196 of the Undervalued European Stocks Based On Cash Flows we have identified here. Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly. Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.
Seeking Other Investments?
Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include BME:PHM HLSE:KOSKI and OM:VITR.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
View Comments
- Global Market Highlights 3 Stocks That May Be Trading Below Their Estimated Value
Feb 17, 2026
In recent weeks, global markets have experienced a mix of volatility and cautious optimism, with U.S. stocks declining amid concerns over AI disruptions and stronger-than-expected job gains dampening hopes for near-term rate cuts. Amid these fluctuating conditions, investors are increasingly on the lookout for undervalued stocks that may offer potential value in a market where indices like the Nasdaq Composite and S&P 500 have faced downward pressure. Identifying such opportunities often involves looking at companies with strong fundamentals that may be temporarily overlooked due to broader market trends or sector-specific challenges.
Top 10 Undervalued Stocks Based On Cash Flows
Name Current Price Fair Value (Est) Discount (Est) Recruit Holdings (TSE:6098) ¥6100.00 ¥12120.19 49.7% Neste Oyj (HLSE:NESTE) €20.54 €41.08 50% Nemetschek (XTRA:NEM) €64.20 €128.11 49.9% Helens International Holdings (SEHK:9869) HK$0.90 HK$1.78 49.6% Galderma Group (SWX:GALD) CHF150.80 CHF299.99 49.7% Fuji Media Holdings (TSE:4676) ¥3552.00 ¥7052.10 49.6% DIGITAL HEARTS HOLDINGS (TSE:3676) ¥861.00 ¥1719.33 49.9% cBrain (CPSE:CBRAIN) DKK70.70 DKK141.04 49.9% B&S Group (ENXTAM:BSGR) €5.85 €11.66 49.8% BEAUTY GARAGE (TSE:3180) ¥1438.00 ¥2851.78 49.6%
Click here to see the full list of 450 stocks from our Undervalued Global Stocks Based On Cash Flows screener.
Here's a peek at a few of the choices from the screener.
Sustained Infrastructure Holding
Overview: Sustained Infrastructure Holding Company is an investment holding company involved in ports, logistics, and water solutions in Saudi Arabia and internationally, with a market cap of SAR2.40 billion.
Operations: The company's revenue is derived from Port Development and Operations (SAR1.21 billion), Logistic Parks and Support Services (SAR153.78 million), and Water Desalination and Distribution (SAR95.53 million).
Estimated Discount To Fair Value: 16%
Sustained Infrastructure Holding is trading at SAR29.5, below its estimated cash flow value of SAR35.13, suggesting it may be undervalued based on cash flows. Earnings are forecast to grow significantly by 22.1% annually over the next three years, outpacing the South African market's growth rate of 7.8%. However, despite this growth potential and a revenue increase forecasted at 10.3% per year, it has an unstable dividend track record and a low return on equity forecast of 8.8%.
In light of our recent growth report, it seems possible that Sustained Infrastructure Holding's financial performance will exceed current levels. Navigate through the intricacies of Sustained Infrastructure Holding with our comprehensive financial health report here.
Story Continues
SASE:2190 Discounted Cash Flow as at Feb 2026
DongHua Testing Technology
Overview: DongHua Testing Technology Co., Ltd. specializes in structural mechanical properties research and solutions for electrochemical workstations in China, with a market cap of CN¥6.08 billion.
Operations: The company's revenue primarily comes from its Instrumentation Testing segment, which generated CN¥533.04 million.
Estimated Discount To Fair Value: 15.4%
DongHua Testing Technology, trading at CN¥44.08, is priced below its estimated cash flow value of CN¥52.08, highlighting potential undervaluation based on cash flows. Revenue is expected to grow 29.3% annually, surpassing the Chinese market's average growth rate of 14.9%. Earnings growth is projected at 33.1% per year over the next three years, with a high forecasted return on equity of 20.8%, despite an unstable dividend track record.
Our comprehensive growth report raises the possibility that DongHua Testing Technology is poised for substantial financial growth. Take a closer look at DongHua Testing Technology's balance sheet health here in our report.SZSE:300354 Discounted Cash Flow as at Feb 2026
Aucnet
Overview: Aucnet Inc. is a circular market design company involved in online auctions and distribution businesses for goods such as flowers, used motorcycles, and used medical equipment, with a market cap of ¥97.42 billion.
Operations: Aucnet's revenue segments include online auctions and distribution services for various goods, including flowers, used motorcycles, and used medical equipment.
Estimated Discount To Fair Value: 18.8%
Aucnet, with its stock trading at ¥2,251, is below the estimated future cash flow value of ¥2,771.74, suggesting potential undervaluation. The company's earnings grew 32% last year and are projected to rise 13.53% annually, outpacing the Japanese market's average growth rate of 9%. Despite a recent dividend decrease and unstable track record, Aucnet's expected revenue growth of 6.5% per year exceeds the JP market's forecasted rate of 5%.
Upon reviewing our latest growth report, Aucnet's projected financial performance appears quite optimistic. Unlock comprehensive insights into our analysis of Aucnet stock in this financial health report.TSE:3964 Discounted Cash Flow as at Feb 2026
Taking Advantage
Click this link to deep-dive into the 450 companies within our Undervalued Global Stocks Based On Cash Flows screener. Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments. Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.
Ready To Venture Into Other Investment Styles?
Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include SASE:2190 SZSE:300354 and TSE:3964.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
View Comments
- European Market Highlights 3 Stocks Priced Below Estimated Value
Feb 17, 2026
As European markets navigate volatility amid concerns about AI disruption and digest better-than-expected U.S. jobs data, the pan-European STOXX Europe 600 Index has managed to reach new highs, albeit with modest gains. In this environment, identifying stocks that are priced below their estimated value can provide investors with potential opportunities for growth, especially when these stocks show strong fundamentals and resilience in uncertain times.
Top 10 Undervalued Stocks Based On Cash Flows In Europe
Name Current Price Fair Value (Est) Discount (Est) Neste Oyj (HLSE:NESTE) €20.54 €41.08 50% Nemetschek (XTRA:NEM) €64.20 €128.11 49.9% Metriks AI. Società Benefit (BIT:MTK) €3.38 €6.64 49.1% KB Components (OM:KBC) SEK39.25 SEK77.43 49.3% Grieg Seafood (OB:GSF) NOK72.70 NOK143.53 49.3% Galderma Group (SWX:GALD) CHF150.80 CHF299.99 49.7% Eltel (OM:ELTEL) SEK9.26 SEK18.35 49.5% Elkem (OB:ELK) NOK26.86 NOK53.16 49.5% cBrain (CPSE:CBRAIN) DKK70.70 DKK141.04 49.9% B&S Group (ENXTAM:BSGR) €5.85 €11.66 49.8%
Click here to see the full list of 196 stocks from our Undervalued European Stocks Based On Cash Flows screener.
We're going to check out a few of the best picks from our screener tool.
Reway Group
Overview: Reway Group S.p.A. operates through its subsidiaries to focus on road and motorway infrastructure rehabilitation in Italy, with a market cap of €434.61 million.
Operations: The company generates revenue primarily from services amounting to €230.51 million and from the sale of goods/materials totaling €1.72 million.
Estimated Discount To Fair Value: 30.8%
Reway Group is trading at €11.2, significantly below its estimated future cash flow value of €16.18, suggesting it may be undervalued based on cash flows. The company's revenue grew by 39.2% last year and is expected to grow annually by 8.2%, outpacing the Italian market's 5.5%. While earnings are forecast to rise by 11.3% per year, debt coverage through operating cash flow remains a concern for potential investors.
Upon reviewing our latest growth report, Reway Group's projected financial performance appears quite optimistic. Dive into the specifics of Reway Group here with our thorough financial health report.BIT:RWY Discounted Cash Flow as at Feb 2026
Trifork Group
Overview: Trifork Group AG offers information technology and business services across Switzerland, Denmark, the United Kingdom, the Netherlands, the United States, and internationally with a market cap of DKK1.65 billion.
Operations: The company's revenue segments include Trifork - Run at €66.35 million, Trifork - Build at €144.97 million, and Trifork - Inspire at €6.66 million.
Estimated Discount To Fair Value: 43.8%
Story Continues
Trifork Group, trading at DKK84.7, is valued significantly below its estimated future cash flow value of DKK150.64, indicating potential undervaluation based on cash flows. The company anticipates earnings growth of 22.2% annually, surpassing the Danish market's 5.4%. However, a low forecasted return on equity and significant insider selling may raise concerns for investors. Recent strategic partnerships and a share buyback program highlight efforts to enhance shareholder value and operational capabilities.
The analysis detailed in our Trifork Group growth report hints at robust future financial performance. Click here and access our complete balance sheet health report to understand the dynamics of Trifork Group.CPSE:TRIFOR Discounted Cash Flow as at Feb 2026
Semperit Holding
Overview: Semperit Holding is a global company that develops, produces, and sells rubber products for the medical and industrial sectors, with a market cap of €274.86 million.
Operations: The company's revenue segments include €362.01 million from Engineered Applications and €291.58 million from Industrial Applications.
Estimated Discount To Fair Value: 16.4%
Semperit Holding, trading at €13.36, is undervalued relative to its estimated future cash flow value of €15.97 and trades at a good value compared to peers. Earnings are forecast to grow significantly, with the company expected to become profitable in three years. However, revenue growth is modest at 7.2% annually and the dividend yield of 3.74% is not well covered by earnings, which could be a concern for income-focused investors.
Our comprehensive growth report raises the possibility that Semperit Holding is poised for substantial financial growth. Get an in-depth perspective on Semperit Holding's balance sheet by reading our health report here.WBAG:SEM Discounted Cash Flow as at Feb 2026
Next Steps
Delve into our full catalog of 196 Undervalued European Stocks Based On Cash Flows here. Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes. Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.
Want To Explore Some Alternatives?
Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include BIT:RWY CPSE:TRIFOR and WBAG:SEM.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
View Comments
